Quick ReadARKG's concentrated, active bet on pre-revenue biotech gained 32% YTD but lost 13 more percentage points than GNOM over the past five years. GNOM suits retirement investors as a core holding; ARKG works best as a satellite bet sized to survive another potential 50% drawdown. SmartAsset's free tool can match you with a financial advisor in minutes to help you answer that today. The ARK Genomic Revolution ETF (CBOE:ARKG) and the Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) look like siblings on any screener. The implicit bet is that genomics as a category compounds even if the flashiest names disappoint.